Abstract
© 2019 Medpharm. Osteoporosis is a common systemic progressive skeletal disease that remains a significant problem worldwide. It is important to understand the pathogenesis and the possible mechanism of action of anti-osteoporotic drugs. Treatment of osteoporosis is strictly related to severity of pathology and consists of prevention of fragility fractures with the correct lifestyle and adequate nutritional supplements. Bisphosphonates are the agents most extensively studied and prescribed in clinical practice for more than 20 years. They give the most effective protection from various fractures including vertebral, hip and other non-vertebral fractures. Bisphosphonates are generally well tolerated and have a favourable safety profile when used in the treatment of osteoporosis. This review aims to provide an overview of the management of osteoporosis with the use of bisphosphonate medicines. The purpose of this review is to focus on the main current pharmacological products available for the treatment of osteoporotic patients.
| Original language | English |
|---|---|
| Pages (from-to) | 30-34 |
| Number of pages | 5 |
| Journal | SA Pharmaceutical Journal |
| Publication status | Published - 1 Jan 2019 |